about
Modulation of pancreatic cancer chemoresistance by inhibition of TAK1Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype.An angiopoietin-like protein 2 autocrine signaling promotes EMT during pancreatic ductal carcinogenesis.TAK1-regulated expression of BIRC3 predicts resistance to preoperative chemoradiotherapy in oesophageal adenocarcinoma patients.Tissue transglutaminase: a new target to reverse cancer drug resistanceMolecular analysis of a male breast cancer patient with prolonged stable disease under mTOR/PI3K inhibitors BEZ235/everolimus.Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells.NF-κB as a target for pancreatic cancer therapy.Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy.Current Strategies to Overcome Resistance to ALK-Inhibitor Agents.Combined inhibition of IL1, CXCR1/2, and TGFβ signaling pathways modulates in-vivo resistance to anti-VEGF treatment.A Case-Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic Markers in Male Breast Cancer.Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT.A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma.EMT and Treatment Resistance in Pancreatic Cancer.Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells.Angiopoietin-Like Proteins in Angiogenesis, Inflammation and Cancer.An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients.Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients.Predictive biomarkers for the treatment of resectable esophageal and esophago-gastric junction adenocarcinoma: from hypothesis generation to clinical validation.Pancreatic Cancer and Obesity: Molecular Mechanisms of Cell Transformation and ChemoresistanceInduction of immunosuppressive functions and NF-κB by FLIP in monocytesImmunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game AroundVorinostat Potentiates 5-Fluorouracil/Cisplatin Combination by Inhibiting Chemotherapy-Induced EGFR Nuclear Translocation and Increasing Cisplatin UptakeImmunoevolution of mouse pancreatic organoid isografts from preinvasive to metastatic disease
P50
Q35143975-E79DF96B-7A1B-4369-A57E-198F5FAFE73FQ35227104-281D78B2-3445-491C-9F3E-00C618DD0E8FQ35955457-A69F5167-D195-41CA-846B-722051A17358Q36081375-8B52BC1B-34A8-460C-B0A2-0D0867193DF6Q36503511-78C1262E-A73E-4937-AA5E-BA59AC6259FCQ36849266-CB4BCCD0-4836-437F-A559-8FFD577227ABQ36907149-6ACF201B-8853-4CBB-B920-0DC2F1E54B54Q37996435-42161D27-F569-4304-A3C4-670C54670F6DQ38103859-79C757D7-E42A-4135-9E94-C66407876694Q38564687-94420885-44F4-4AB5-808B-5460842B8E57Q38827476-123A4681-6063-40E8-ADF0-A4A2F36015CCQ39093555-FCBFA6FE-F7DA-48FF-9386-D23EB921B614Q39268578-FF30D580-C85C-493B-89E9-D60BD6F4458CQ39527047-B27CE5A2-2702-4435-AC19-C6544A801826Q41067756-9B805999-24B2-43CC-B6BD-D5E6B91A8E89Q41670877-37A86738-7232-4917-B443-CA0BBFCEC14EQ46629247-E08CB1EF-B9DA-4EA7-A22C-86EF55A534B1Q47699400-E7EB8E57-45AB-4527-9A45-82AE53F409D7Q50801948-C1B6CEED-E571-44CF-A6B4-6033FFE29FF3Q51097854-F858D54E-CDC6-45CF-8666-5067F37A0F7CQ52653776-4502C36D-F687-4A88-958B-8531CADF86B2Q58117029-055FC8E4-6C79-4E99-A43E-05A78B6178FDQ59792591-FFBDD1A0-8B89-467B-85B6-E608FB7203B0Q90166631-39398C0E-A5A3-4812-BFDA-883D65BEF317Q92569890-2DEA52DC-7F82-4312-BBCB-81FE4DC402E8Q92689135-200C81B7-C375-4E25-A888-8D7EA67A8D3FQ92797185-66C08A6C-29F6-4EF4-AEB1-3063A994275F
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Carmine Carbone
@ast
Carmine Carbone
@en
Carmine Carbone
@es
Carmine Carbone
@nl
Carmine Carbone
@sl
type
label
Carmine Carbone
@ast
Carmine Carbone
@en
Carmine Carbone
@es
Carmine Carbone
@nl
Carmine Carbone
@sl
prefLabel
Carmine Carbone
@ast
Carmine Carbone
@en
Carmine Carbone
@es
Carmine Carbone
@nl
Carmine Carbone
@sl
P1053
L-1009-2016
P106
P1153
42061095800
P21
P31
P3829
P496
0000-0001-5168-747X